Data from a phase I expansion cohort revealed that bintrafusp-alfa had encouraging efficacy and manageable tolerability in patients with advanced platinum-experienced NSCLC not previously treated with ICIs, particularly in patients with PD-L1–high tumors. The gene discussed is CD274; the disease is non-small cell lung carcinoma.